Research ArticleBRIEF COMMUNICATION
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
Masatoshi Hotta, Andrei Gafita, Johannes Czernin and Jeremie Calais
Journal of Nuclear Medicine October 2022, 63 (10) 1484-1488; DOI: https://doi.org/10.2967/jnumed.121.263441
Masatoshi Hotta
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Andrei Gafita
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Johannes Czernin
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Jeremie Calais
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 10
October 1, 2022
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
Masatoshi Hotta, Andrei Gafita, Johannes Czernin, Jeremie Calais
Journal of Nuclear Medicine Oct 2022, 63 (10) 1484-1488; DOI: 10.2967/jnumed.121.263441
Jump to section
Related Articles
Cited By...
- Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
- Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
- Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy
- 177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers
- Reply: What Does an Imaging "Selection" Claim Actually Mean?